1006.65
-1.10%
ICICI Securities Limited
Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.
Tatva Chintan Pharma.. has an average target of 883.00 from 2 brokers.
More from Tatva Chintan Pharma Chem Ltd.
Recommended